- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03395587
Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma (GlioVax)
Phase II Trial of Vaccination With Lysate-loaded, Mature Dendritic Cells Integrated Into Standard Radiochemotherapy in Newly Diagnosed Glioblastoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Michael Sabel, Prof. MD
- Phone Number: +49 211 8116276
- Email: Michael.Sabel@med.uni-duesseldorf.de
Study Contact Backup
- Name: Marion Rapp, PD MD
- Phone Number: +49 211 8107458
- Email: Marion.Rapp@med.uni-duesseldorf.de
Study Locations
-
-
-
Krefeld, Germany, 47805
- Recruiting
- Helios Klinikum Krefeld, Klinik für Neurochirurgie
-
Contact:
- Michael Stoffel, Prof. MD
- Phone Number: +492151321320
- Email: Michael.Stoffel@helios-gesundheit.de
-
Principal Investigator:
- Michael Stoffel, Prof. MD
-
Sub-Investigator:
- Knut Send, MD
-
-
NRW
-
Lünen, NRW, Germany, 44534
- Recruiting
- St. Marien Hospital Lünen, Klinik für Neurochirurgie
-
Contact:
- Konstantinos Gousias, PD Dr. Dr.
- Phone Number: 3151 +49230677
- Email: cn@klinikum-luenen.de
-
-
Northrhine Westphalia
-
Bochum, Northrhine Westphalia, Germany, 44829
- Recruiting
- Klinik für Neurologie, Knappschaftskrankenhaus Bochum
-
Contact:
- Uwe Schlegel, Prof. MD
- Phone Number: 00492342993719
- Email: neurologie@kk-bochum.de
-
Contact:
- Rekowski Sylvia
- Phone Number: 00492342993719
- Email: sylvia.rekowski@kk-bochum.de
-
Sub-Investigator:
- Thomas Kowalski
-
Principal Investigator:
- Uwe Schlegel, Prof. MD
-
Duisburg, Northrhine Westphalia, Germany, 47055
- Recruiting
- Klinik für Neurochirurgie, Sana Kliniken Duisburg
-
Contact:
- Jung Su Zin, Dr. med.
- Phone Number: 00492037332401
- Email: suzin.jung@sana.de
-
Principal Investigator:
- Catharina Junghans, Dr. med.
-
Sub-Investigator:
- Jung Su Zin, Dr. med.
-
Düsseldorf, Northrhine Westphalia, Germany, 40225
- Recruiting
- Neurochirurgische Klinik, Universitätsklinikum Düsseldorf
-
Contact:
- Michael C. Sabel, Prof. MD
- Phone Number: 00492118116276
- Email: michael.sabel@med.uni-duesseldorf.de
-
Contact:
- Natalie Sevens
- Phone Number: 00492118117881
-
Sub-Investigator:
- Marion Rapp, PD MD
-
Principal Investigator:
- Michael Sabel, Prof. MD
-
Münster, Northrhine Westphalia, Germany, 48149
- Recruiting
- Klinik für Allgemeine Neurologie, Universitätsklinikum Münster
-
Contact:
- Oliver Grauer, PD Dr. med.
- Phone Number: 0492518346814
- Email: oliver.grauer@ukmuenster.de
-
Principal Investigator:
- Oliver Grauer, PD Dr. med.
-
Sub-Investigator:
- Marc Pawlitzki, Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Determined at pre-screening (prior to surgery; wk-3 - wk-1):
- Patients ≥ 18 years of age at surgery.
- Patients must be in a cognitive state to understand and sign the informed consent indicating that they are aware of the investigational nature and procedures of the study.
- First written informed consent for screening for eligibility, including tumor tissue collection, transfer and processing, central neuropathological evaluation of Tumor sample, central neuroradiological assessment of extent of resection, infectious disease (HIV, HBV, HCV, Treponema pallidum) testing, determination of MGMT promoter methylation status and pregnancy testing.
Determined at screening (at and post-surgery; d0 - wk3):
- Newly diagnosed, monofocal GBM, IDH wildtype (WHO grade IV), including the histological variants of gliosarcoma and giant cell glioblastoma, confirmed by central neuropathologist according to the WHO classification of central nervous System tumors 2016. Tumors may cross into, but not beyond the corpus callosum.
- Near-complete resection (≤ 5 ml residual contrast enhancing tumor volume) confirmed by central neuroradiologist on MRI scan within 72 h postoperative; awake surgery and second look surgery are possible, if medically indicated.
- Sterile tumor sample of ≥ 150 mg with tumor cell frequency ≥ 60% as determined by central neuropathologist available for vaccine production.
- Successful production of sterile, avital tumor lysate.
- Karnofsky performance status ≥ 70%.
- Adequate hepatic (serum glutamate pyruvate transferase/alanine transaminase (SGPT/ALT), serum glutamic oxaloacetate transaminase/aspartate transaminase (SGOT/AST) and alkaline phosphatase ≤ 3-times upper limit of normal (ULN); bilirubin ≤ 1.5-times ULN) and renal functions (creatinine ≤ 1.5-times ULN).
- Adequate bone marrow function (hemoglobin ≥ 10 g/dl, thrombocytes ≥ 100,000/μl, white blood cell count ≥ 3,000/μl; neutrophil count ≥ 1,500/μl).
- Prothrombin time (PT) and activated partial thromboplastin time (PTT) ≤ 1.6x ULN unless therapeutically warranted. International normalized ratio (INR) (in absence of anticoagulation treatment) ≤ 1.5.
- Systemic corticosteroids tapered down to ≤ 2 mg of dexamethasone or equivalent per day within 7 days postoperative (use of corticosteroids during the treatment period should be avoided, however it is possible if clinically indicated, but may require interruption of dendritic cell vaccination).
- Female patients with reproductive potential and male generative patients and their female partners must agree to be true abstinent or to use a highly effective form of contraception (pearl index < 1%) during the trial.
- Patients must be in a cognitive state to understand and sign the informed consent indicating that they are aware of the investigational nature and procedures of the study.
- Written informed consent to participate in study.
Exclusion Criteria:
determined at pre-screening (prior to surgery; wk-3 - wk-1):
- Medical history of severe acute or chronic disease with poor prognosis, e.g. severe coronary heart disease, heart failure (New York Heart Association classes III/IV), severe poorly controlled diabetes, severe mental retardation or other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
- Medical history of severe autoimmune disorder or immunodeficiency or patients with organ allograft.
- Medical history of bleeding diathesis or coagulopathy.
- Prior malignancy during the last three years except non-melanoma skin cancer, in situ cervical cancer, treated superficial bladder cancer or cured, early-stage prostate cancer in a patient with prostate-specific antigen (PSA) level less than ULN.
- Previous radiotherapy to head and neck.
- Known allergy or intolerability to TMZ, dacarbazine, the contrast agent or to components of the dendritic cell vaccine.
- Current treatment of glioblastoma in another clinical trial with therapeutic intervention or current use of any other investigational agent.
- Known pregnancy or breast feeding.
- No known severe infection requiring treatment.
- Accommodation in an institution due to legal orders (§40(4) AMG).
- Evidence of current drug or alcohol abuse. determined at screening (at and post-surgery; d0 - wk3):
- Infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or Treponema pallidum or other severe infection requiring treatment.
- Accommodation in an institution due to legal orders (§40(4) AMG).
- Pregnant or breast feeding female patients. From pre-menopausal female patients with childbearing potential a negative pregnancy test must be obtained.
- Any psycho-social condition hampering compliance with the study protocol.
- MGMT promoter methylation status equivocal.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental intervention
Fluorescence-guided surgery (day 0) Leukapheresis (wk4) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) vaccination with autologous, tumor lysate-loaded, mature dendritic cells (DC) (7x, 2 - 10 x 106 DC each, intradermal injection, weekly wk11-14, wk17, 21, 25)Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)
|
Advanced therapy medicinal product (ATMP) produced at the University Hospital Düsseldorf according to Good Manufacturing Practice (GMP) with production permission according §13 AMG (German Drug Law) of the local authorities (Bezirks¬regierung Düsseldorf)
Other Names:
|
Other: Control intervention
Standard therapy: Fluorescence-guided surgery (day 0) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35) |
temozolomide, fractionated radiochemotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Day of surgery until death of any cause assessed up to 34 months
|
Overall survival as measured from the day of surgery until death from any cause assessed up to 34 months
|
Day of surgery until death of any cause assessed up to 34 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: Day of surgery until day of diagnosis of tumor progression assessed upto 34 months
|
Progression-free survival as measured from the day of surgery until diagnosis of tumor progression by MRI scan according to modified Response Assessment in Neuro-Oncology (RANO) criteria assessed up to 34 months
|
Day of surgery until day of diagnosis of tumor progression assessed upto 34 months
|
OS rates
Time Frame: 6, 12 and 24 months after the day of surgery
|
OS rates at 6, 12 and 24 months after the day of surgery
|
6, 12 and 24 months after the day of surgery
|
PFS rates
Time Frame: 6, 12 and 24 months after the day of surgery
|
PFS rates at 6, 12 and 24 months after the day of surgery
|
6, 12 and 24 months after the day of surgery
|
Frequency and severity of adverse events
Time Frame: 34 months
|
Safety based on the frequency and severity of adverse events (AE) with toxicity graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 4.03 (CTCAE 4.03)
|
34 months
|
Karnofsky Performance Status
Time Frame: 34 months
|
Overall and neurological performance based on the Karnofsky performance status (MMSE-2)
|
34 months
|
MMSE-2
Time Frame: 34 months
|
Overall and neurological performance based on the Minimal Mental State Examination 2 (MMSE-2)
|
34 months
|
Quality of life of cancer patients
Time Frame: 34 months
|
Quality of life as determined by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 3.0
|
34 months
|
Quality of life in patients with brain cancer
Time Frame: 34 months
|
Quality of life as determined by the European Organization for Research and Treatment of Cancer (EORTC) Brain Cancer Module QLQ-BN20
|
34 months
|
Psychological distress in oncology patients
Time Frame: 34 months
|
Quality of life as determined by the Distress Thermometer (DT)
|
34 months
|
Psychological distress, anxiety and depression
Time Frame: 34months
|
Quality of life as determined by the Hospital Anxiety and Depression Scale (HADS) for psycho-oncological strain assessment
|
34months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Michael Sabel, Prof. MD, Department of Neurosurgery
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
Other Study ID Numbers
- GlioVax
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Autologous, tumor lysate-loaded, mature dendritic cells (DC)
-
Erasmus Medical CenterCompleted
-
UMC UtrechtRadboud University Medical Center; ZonMw: The Netherlands Organisation for... and other collaboratorsRecruitingRheumatoid ArthritisNetherlands
-
N.N. Petrov National Medical Research Center of...UnknownSarcoma | Neoplasms, Connective and Soft TissueRussian Federation
-
University Hospital ErlangenUniversity Hospital, Essen; University Hospital Tuebingen; Universitätsklinikum... and other collaboratorsActive, not recruiting
-
Inge Marie SvaneCompleted
-
Lisata Therapeutics, Inc.TerminatedStage IV Melanoma | Stage III MelanomaUnited States
-
PrimeVax Immuno-Oncology Inc.Walter Reed Army Institute of Research (WRAIR)Not yet recruitingAdvanced Melanoma
-
Rockefeller UniversityMemorial Sloan Kettering Cancer CenterCompleted
-
The Republican Research and Practical Center for...Belarusian State Medical UniversityCompletedPancreatic Neoplasms | Dendritic CellsBelarus
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Completed